Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does USTEKINUMAB Cause Upper respiratory tract infection? 606 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 606 reports of Upper respiratory tract infection have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 0.7% of all adverse event reports for USTEKINUMAB.

606
Reports of Upper respiratory tract infection with USTEKINUMAB
0.7%
of all USTEKINUMAB reports
243
Deaths
216
Hospitalizations

How Dangerous Is Upper respiratory tract infection From USTEKINUMAB?

Of the 606 reports, 243 (40.1%) resulted in death, 216 (35.6%) required hospitalization, and 135 (22.3%) were considered life-threatening.

Is Upper respiratory tract infection Listed in the Official Label?

Yes, Upper respiratory tract infection is listed as a known adverse reaction in the official FDA drug label for USTEKINUMAB.

What Other Side Effects Does USTEKINUMAB Cause?

Drug ineffective (12,471) Off label use (10,990) Product dose omission issue (9,405) Fatigue (5,457) Product use issue (5,008) Psoriasis (4,955) Pain (4,872) Rash (4,736) Crohn's disease (4,662) Arthralgia (4,608)

What Other Drugs Cause Upper respiratory tract infection?

ADALIMUMAB (3,306) ETANERCEPT (2,948) TOFACITINIB (1,805) RITUXIMAB (1,713) ABATACEPT (1,623) METHOTREXATE (1,576) TOCILIZUMAB (1,455) APREMILAST (1,437) PREDNISONE (1,354) SECUKINUMAB (1,339)

Which USTEKINUMAB Alternatives Have Lower Upper respiratory tract infection Risk?

USTEKINUMAB vs USTEKINUMAB-STBA USTEKINUMAB vs VADADUSTAT USTEKINUMAB vs VALACYCLOVIR USTEKINUMAB vs VALBENAZINE USTEKINUMAB vs VALBENAZINE DITOSYLATE

Related Pages

USTEKINUMAB Full Profile All Upper respiratory tract infection Reports All Drugs Causing Upper respiratory tract infection USTEKINUMAB Demographics